Chris is a specialist in investigative liver pathology and has focused his career on translational-stage through definitive Phase 2 /pivotal drug development in metabolic disease and oncology. He co-chaired the 2019 Keystone Symposium in non-alcoholic steatohepatitis (NASH) and is a member of the Liver Forum.

Previously, he was the CEO/General Manager at SmartZyme Biopharma, an OrbiMed portfolio company, that specializes in protein engineering. He started his career at Genentech. Dr. Shepard has supported over $1.5bn in investments and transactions in biotechnology/pharma spanning research, drug program development, combination product development, clinical trial design, and personalized medicine and biomarkers.